Although no current clinical trials are studying the effects of anti-apoptotic Bcl-2 family member inhibition in breast cancers alone, initial Phase I studies in small cell lung cancers suggest that ABT-263 is safe and well tolerated in patients with solid tumors [49]. Here, BCL2 is linked to breast cancer.